Kosan Biosciences: welcoming new found orphan status.
In: PharmaWatch: Cancer, Jg. 3 (2004-12-01), Heft 12, S. 14-14
report
Zugriff:
Reports that Kosan Biosciences Inc. has initiated Phase I dose escalating trials for 17-allylamino-17-demethoxy-geldanamycin (17-AGG) in patients with refractory or relapsed multiple myeloma. Description on how 17-AGG works in cancer cells; Potential benefits of the orphan drug status to Kosan Biosciences; Clinical characteristics of multiple myeloma.
Titel: |
Kosan Biosciences: welcoming new found orphan status.
|
---|---|
Zeitschrift: | PharmaWatch: Cancer, Jg. 3 (2004-12-01), Heft 12, S. 14-14 |
Veröffentlichung: | 2004 |
Medientyp: | report |
Schlagwort: |
|
Sonstiges: |
|